Rep. Schrader’s Bill to Reauthorize Animal Drug User Fee Act Passes Out of Committee
Congressman Kurt Schrader’s (OR-05) bipartisan bill (H.R. 5554) to reauthorize the Food and Drug Administration’s (FDA) Animal Drug User Fee Act (ADUFA) and Animal Generic Drug User Fee Act (AGDUFA) passed out of his Energy and Commerce Committee unanimously. ADUFA and AGDUFA would continue agreements between the FDA and the animal drug industry to pay user fees that help speed the approval of new drugs for farmers, ranchers, families, and veterinarians so they can keep their animals and pets safe and healthy.
The committee also unanimously adopted Rep. Schrader’s bipartisan amendment to expand conditional approval of animal drugs. This would expand opportunities for drugs that meet specific requirements to reach the market and fill unmet animal medical needs.
“As a veterinarian, I'm acutely aware that a lot of the great innovations that occur in the human pharmaceutical world are unavailable for long periods of time to veterinarians and animals,” said Rep. Schrader. “There isn’t a robust bandwidth to engage the pharmaceutical industry to develop these drugs. So the conditional approval process is critical to gain access to these drugs under a very specific criteria to make sure our four footed friends have some of the greatest and latest innovations that our human folks do. I’m pleased that our bipartisan, broadly supported amendment and bill were unanimously supported by my colleagues on the committee and I look forward to bringing it to the Floor soon.”
Rep. Schrader introduced the legislation last month with Congressman Markwayne Mullin (R-OK-02). ADUFA and AGDUFA give the FDA authority to collect user fees from sponsors for the review of animal drug applications. ADUFA was first authorized in 2003, giving the FDA authority for the first time to collect user fees for the review of animal drugs similar to fee programs for human drugs and medical devices. AGDUFA, authorized in 2008, gave the FDA the same authority but for generic drug applications. The current reauthorization of both ADUFA and AGDUFA expires on September 30, 2018.
Tags: Animal Welfare